Additional Study Data Showed 70 Percent of Patients had Improved or Stabilized Cognition Following Treatment with Copaxone®
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced preliminary data from two studies, Coptimize and Qual…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced preliminary data from two studies, Coptimize and Qual…
. - Early Initiation of Treatment with Copaxone® Reduced the Risk of Developing MS by 41 Percent - Copaxone® Delayed T…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced positive results from a study assessing a new lower-v…
. - Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis…
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies supporting the company's inn…
. - More than 80 percent of patients were able to walk unassisted following 15 years of treatment and average disease d…